Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report)’s stock price fell 1.2% during trading on Thursday . The company traded as low as $4.03 and last traded at $4.04. 170,644 shares changed hands during mid-day trading, a decline of 35% from the average session volume of 261,100 shares. The stock had previously closed at $4.09.
Aadi Bioscience Stock Up 2.9%
The stock has a fifty day moving average of $4.30 and a 200-day moving average of $4.11. The stock has a market capitalization of $103.73 million, a price-to-earnings ratio of -1.84 and a beta of 0.68.
About Aadi Bioscience
Aadi Bioscience, Inc is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers. Its work has centered on treatments that target molecular pathways involved in tumor growth, with an emphasis on rare and underserved oncology indications.
The company’s principal product is FYARRO (sirolimus protein-bound particles for injectable suspension), also known as nab-sirolimus. The U.S. Food and Drug Administration approved FYARRO in 2021 for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, a rare form of cancer.
Featured Articles
- Five stocks we like better than Aadi Bioscience
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
- MarketBeat Week in Review – 09/14 – 09/18
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
